SNOA News and Press, Sonoma Pharmaceuticals Inc. From 07/28/20

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions and the MicroSafe Group Dubai announce that Microsafe&#x...

Sonoma Pharmaceuticals (NASDAQ: SNOA ): Q4 GAAP EPS of -$0.77. More news on: Sonoma Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Reduction in Year-Over-Year Net Loss by 75% Total Revenues Flat Year-Over-Year at $18.9 million Strong International Growth with 53% Increased Product Revenues Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hy...

Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...

 Gainers:  Sonoma Pharmaceuticals (NASDAQ: SNOA ) +145% . More news on: Sonoma Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, Phio Pharmaceuticals Corp., Stocks on the move, , Read more ...

Will You Add these To Your List Of Penny Stocks? No matter if you trade penny stocks or look for ways of investing in penny stocks , there are certainly plenty of choices in the stock market today. But it’s important to remember that there are factors in play that can change your ini...

Sonoma Pharmaceuticals (NASDAQ: SNOA ) +162%  on COVID-19 nod in Australia for disinfectant. More news on: Sonoma Pharmaceuticals, Inc., Phio Pharmaceuticals Corp., Adaptimmune Therapeutics plc, Stocks on the move, , Read more ...

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce a...

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, is pleased to announce that it received a new CE Markin...

Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...